EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
- 26 November 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 15 (1) , 63-74
Abstract
Importance of the field: Recent advances in the understanding of the oncogenesis of head and neck squamous cell carcinomas (HNSCC) have revealed multiple dysregulated signaling pathways. One freque...Keywords
This publication has 113 references indexed in Scilit:
- Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck CancerInternational Journal of Radiation Oncology, Biology, Physics, 2010
- Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patientsThe Laryngoscope, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Targeting EGFR resistance networks in head and neck cancerCellular Signalling, 2009
- Chromosomal imbalances in oral squamous cell carcinoma: Examination of 31 cell lines and review of the literatureOral Oncology, 2008
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005